Diamond Ranch Foods (PLPL) 0.3500 $PLPL
Plandai Biotechnology Expects Pfizer Viagra Patent Ruling Will Aid in Developing All-Natural Substitute to Treat Erectile Dysfunction
Marketwire - Mon Sep 29, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) has already begun cultivating and cloning the epimedium plants it recently acquired as part of its preliminary plans to develop and test what it anticipates will be an all-natural substitute for the widely popular erectile dysfunction (ED) drugs Viagra(R), Cialis(R) and Levitra(R).
Plandai Biotechnology Plans to Develop Extract to Enter Lucrative Erectile Dysfunction Market With All-Natural Substitute for Viagra(R)
Marketwire - Mon Sep 22, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(R) and Cialis(R).
Plandai Biotechnology, Inc. to Develop All-Natural Phytofare(TM) Extract for Erectile Dysfunction
Marketwire - Wed Sep 17, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the acquisition of a strain of epimedium with high levels of icariin, the primary active compound in herbal epimedium, to develop an all-natural Phytofare(TM) extract for erectile dysfunction for further testing with the expectation that the extract could be sold as an active ingredient to pharmaceutical and nutraceutical manufacturers.
Plandai Biotechnology Gains Competitive Advantage With Preliminary Clinical Trial Results
Marketwire - Mon Sep 15, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) expects to begin commercial production of its green tea extract, Phytofare(TM) Catechin Complex, in the coming weeks when the first green tea crop of the season is ready for processing at the company's 8,000 acre Senteeko facility in South Africa. After receiving positive preliminary results from a human clinical trial that showed Plandai's product offers ten times more bioavailability than the commercially available extract it was compared to, the company could gain a competitive advantage over other less potent extracts.
Plandai Biotechnology's Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial Conducted in South Africa
Marketwire - Wed Sep 10, 8:04AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company's green tea extract, Phytofare(TM) Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, Plandai's Phytofare(TM) extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10.
Plandaí Biotechnology, Inc. Announces Preliminary Results of Study Showing Phytofaretm Catechin Complex Having Ten Times The Greater Bioavailability Than Generic Green Tea Extracts
ACCESSWIRE - Thu Sep 04, 8:11AM CDT
Greater Bioavailability Allows the Body to Experience More of the Positive Health Benefits of the Green Tea
Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company's Production Facility and Start of Commercial Production
ACCESSWIRE - Wed Aug 06, 8:25AM CDT
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
Planda Biotechnology, Inc. Provides Shareholder Update on Completion of the Companys Production Facility and Start of Commercial Production
eTeligis - Wed Aug 06, 8:11AM CDT
SEATTLE, WA, United States, via ETELIGIS INC., 08/06/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company's state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
Plandai Biotechnology, Inc. Announces Support of ICCCO -- the World's First International Cannabis Trade Association
Marketwire - Mon Jul 07, 8:01AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced its support for the formation of the International Coalition of Cannabis Companies and Organizations (ICCCO), the world's first international cannabis trade association co-founded by Plandai director, Jamen Shively. ICCCO was recently formed to deliver on the demands of citizens worldwide: the creation and maintenance of a global cannabis industry, which enforces social responsibility, generates jobs and tax revenues, and ensures consistent standards.
OTC Stocks Daily Trading Focus: Neutra Corporation, Terra Tech Corp, Plandai Biotechnology, Inc. Nano Tech Entertainment, Inc. Techprecision Corp.
PR Newswire Europe - Thu Jul 03, 7:01AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
Marketwire - Thu Jun 26, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare(TM) Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Marketwire - Tue Jun 24, 8:15AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai's Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Can Be Used as a Dietary Supplement Without Prior FDA Notification or Approval
Marketwire - Wed Jun 18, 7:55AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has received a legal opinion from the noted law firm of Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug legal firm in the country, in which it was determined that Plandai will not be required to apply to the US Food and Drug Administration for approval to market and sell its Phytofare(TM) Catechin Complex as a dietary supplement. This opinion paves the way for Plandai to immediately commence sales efforts in the United States.
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Marketwire - Tue Apr 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
Plandai Biotechnology Expects Pfizer Viagra Patent Ruling Will Aid in Developing All-Natural Substitute to Treat Erectile Dysfunction
Marketwire - Mon Sep 29, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) has already begun cultivating and cloning the epimedium plants it recently acquired as part of its preliminary plans to develop and test what it anticipates will be an all-natural substitute for the widely popular erectile dysfunction (ED) drugs Viagra(R), Cialis(R) and Levitra(R).
Plandai Biotechnology Plans to Develop Extract to Enter Lucrative Erectile Dysfunction Market With All-Natural Substitute for Viagra(R)
Marketwire - Mon Sep 22, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(R) and Cialis(R).
Plandai Biotechnology, Inc. to Develop All-Natural Phytofare(TM) Extract for Erectile Dysfunction
Marketwire - Wed Sep 17, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the acquisition of a strain of epimedium with high levels of icariin, the primary active compound in herbal epimedium, to develop an all-natural Phytofare(TM) extract for erectile dysfunction for further testing with the expectation that the extract could be sold as an active ingredient to pharmaceutical and nutraceutical manufacturers.
Plandai Biotechnology Gains Competitive Advantage With Preliminary Clinical Trial Results
Marketwire - Mon Sep 15, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) expects to begin commercial production of its green tea extract, Phytofare(TM) Catechin Complex, in the coming weeks when the first green tea crop of the season is ready for processing at the company's 8,000 acre Senteeko facility in South Africa. After receiving positive preliminary results from a human clinical trial that showed Plandai's product offers ten times more bioavailability than the commercially available extract it was compared to, the company could gain a competitive advantage over other less potent extracts.
Plandai Biotechnology's Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial Conducted in South Africa
Marketwire - Wed Sep 10, 8:04AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company's green tea extract, Phytofare(TM) Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, Plandai's Phytofare(TM) extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10.
Plandaí Biotechnology, Inc. Announces Preliminary Results of Study Showing Phytofaretm Catechin Complex Having Ten Times The Greater Bioavailability Than Generic Green Tea Extracts
ACCESSWIRE - Thu Sep 04, 8:11AM CDT
Greater Bioavailability Allows the Body to Experience More of the Positive Health Benefits of the Green Tea
Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company's Production Facility and Start of Commercial Production
ACCESSWIRE - Wed Aug 06, 8:25AM CDT
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
Planda Biotechnology, Inc. Provides Shareholder Update on Completion of the Companys Production Facility and Start of Commercial Production
eTeligis - Wed Aug 06, 8:11AM CDT
SEATTLE, WA, United States, via ETELIGIS INC., 08/06/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company's state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
Plandai Biotechnology, Inc. Announces Support of ICCCO -- the World's First International Cannabis Trade Association
Marketwire - Mon Jul 07, 8:01AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced its support for the formation of the International Coalition of Cannabis Companies and Organizations (ICCCO), the world's first international cannabis trade association co-founded by Plandai director, Jamen Shively. ICCCO was recently formed to deliver on the demands of citizens worldwide: the creation and maintenance of a global cannabis industry, which enforces social responsibility, generates jobs and tax revenues, and ensures consistent standards.
OTC Stocks Daily Trading Focus: Neutra Corporation, Terra Tech Corp, Plandai Biotechnology, Inc. Nano Tech Entertainment, Inc. Techprecision Corp.
PR Newswire Europe - Thu Jul 03, 7:01AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
Marketwire - Thu Jun 26, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare(TM) Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Marketwire - Tue Jun 24, 8:15AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai's Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Can Be Used as a Dietary Supplement Without Prior FDA Notification or Approval
Marketwire - Wed Jun 18, 7:55AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has received a legal opinion from the noted law firm of Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug legal firm in the country, in which it was determined that Plandai will not be required to apply to the US Food and Drug Administration for approval to market and sell its Phytofare(TM) Catechin Complex as a dietary supplement. This opinion paves the way for Plandai to immediately commence sales efforts in the United States.
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Marketwire - Tue Apr 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
